var data={"title":"Cefotaxime: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefotaxime: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5840?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefotaxime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefotaxime: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefotaxime: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147493\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Claforan in D5W [DSC];</li>\n      <li>Claforan [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147494\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cefotaxime Sodium For Injection;</li>\n      <li>Claforan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147542\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Third Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147497\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b>  IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated infections:</i> IM, IV: 1 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate-to-severe infections:</i> IM, IV: 1 to 2 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Life-threatening infections:</i> IV: 2 g every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization:</b> IV: 2 g every 4 to 6 hours for 5 to 7 days (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Arthritis (septic):</b> IV: 1 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial enteric infections in HIV-infected patients (empiric treatment) (off-label use):</b> IV: 1 g every 8 hours (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal) (off-label use):</b> IV: 1 to 2 g every 6 to 8 hours in combination with clindamycin or metronidazole for anaerobic coverage (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain abscess, meningitis:</b> IV: 2 g every 4 to 6 hours in combination with other antimicrobial therapy as warranted (Kowlessar 2006; Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cesarean section:</b> IM, IV: 1 g IV as soon as the umbilical cord is clamped, then 1 g IV or IM at 6  and 12 hours after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Complicated community-acquired intra-abdominal infection of mild-to-moderate severity, including hepatic abscess (in combination with metronidazole):</b> IV: 1 to 2 g every 6  to 8 hours for 4 to 7 days (provided source controlled). <b>Note:</b> For severe infections consider other antimicrobial agents (Bradley, 1987; Kim 2010; Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonorrhea, uncomplicated infection of the cervix, urethra, or rectum:  Note: </b> CDC STD guidelines do not recommend   cefotaxime as a treatment option for uncomplicated gonorrhea; ceftriaxone is the preferred cephalosporin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated gonorrhea of the cervix or urethra (males or females) or of the rectum (females):</i> Manufacturer&rsquo;s labeling: IM: 0.5 g as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated gonorrhea of the rectum (males):</i> Manufacturer&rsquo;s labeling IM: 1 g as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonorrhea, disseminated infections (arthritis and arthritis-dermatitis syndrome) (alternative to preferred therapy) (off-label use):</b> IV: 1 g every 8 hours in combination with azithromycin.  Continue for 24 to 48 hours after improvement begins, then switch to oral therapy guided by antimicrobial susceptibility testing. Total duration of therapy at least 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (as an alternative to ceftriaxone):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiac manifestations:</i> IV: 2 g every 8 hours for 14 to 21 days (Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CNS manifestations:</i> IV: 2 g every 8 hours for 10 to 28 days (Halperin 2007; Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (CAP):</b> IV: 1 to 2 g every 8 hours (Lim 2009). For critically-ill patients (empiric therapy), use in combination with azithromycin or a respiratory fluoroquinolone (eg, levofloxacin or moxifloxacin) or in non-critically ill patients (empiric therapy), use in combination with a macrolide (preferred) or doxycycline; duration of therapy is &ge;5 days (IDSA/ATS [Mandell 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> IV: 1 g within 60 minutes prior to surgical incision. Doses may be repeated in 3 hours if procedure is lengthy or if there is excessive blood loss. <b>Note:</b> preferred agent (with ampicillin) in liver transplantation (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Obesity:</i> The ASHP/IDSA/SIS/SHEA guidelines recommend that for patients weighing &ge;120 kg (or alternatively defined as BMI &gt;30 kg/m<sup>2</sup>), a dose of 2 g within 60 minutes prior to surgical incision should be administered (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spontaneous bacterial peritonitis (off-label dose):</b> IV: 2 g every 8 hours (AASLD [Runyon 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sepsis:</b> IV: 2 g every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Polymicrobial infection:</i> IV: 2 g every 6 hours, in combination with metronidazole or clindamycin for empiric therapy of polymicrobial infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Necrotizing infection due to Vibrio vulnificus:</i> IV: 2 g every 8 hours, in combination with doxycycline. Continue until further debridement is not necessary, patient has clinically improved, and   patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147520\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefotaxime: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range for susceptible infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;50 kg: IM, IV: 50 to 180 mg/kg/day in divided doses every 4 to 6 hours (maximum dose: 12 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;50 kg: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate recommendations (Red Book [AAP] 2012): IM, IV:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infection: 50 to 180 mg/kg/day in divided doses every 6 to 8 hours (maximum dose: 6 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infection: 200 to 225 mg/kg/day in divided doses every 4 to 6 hours; up to 300 mg/kg per day has been used for meningitis (maximum dose: 12 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization (off-label use):</b> Children: IV: 100 to 200 mg/kg/day divided every 6 hours for 10 to 14 days (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Arthritis (septic):</b> Children &ge;50 kg or Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial enteric infections in HIV-infected patients (empiric treatment) (off-label use):</b> Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Brain abscess:</b> Children &ge;50 kg or Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cesarean section:</b> Children &ge;50 kg or Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Complicated community-acquired intra-abdominal infection (in combination with metronidazole):</b> Infants and Children: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment (off-label use):</b> Children and Adolescents: IV: 200 mg/kg/<b>day</b> in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b>; treat for at least 4 to 6 weeks; longer durations may be necessary; may use in combination with gentamicin for some organisms (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonorrhea (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated gonococcal infection (DGI):</i> IV, IM: 25 mg/kg every 12 hours for 7 days; continue for 10 to 14 days if meningitis is documented (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Gonococcal scalp abscesses:</i> IV, IM: 25 mg/kg every 12 hours for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated infections (arthritis and arthritis-dermatitis syndrome) (alternative to preferred therapy):</i> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease (as an alternative to ceftriaxone):</b> <i>Cardiac or CNS manifestations:</i> Infants and Children: IV: 150 to 200 mg/kg/day in divided doses every 6 to 8 hours for 14 to 28 days; maximum daily dose: 6 g daily (Halperin 2007; Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis (in combination with vancomycin):</b> Infants and Children: IV: 225 to 300 mg/kg/day in divided doses every 6 to 8 hours (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired (IDSA/PIDS 2011):</b> Infants &gt;3 months and Children: IV: <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Empiric treatment, <i>Haemophilus influenzae</i>, group A <i>Streptococcus</i>, or <i>S. pneumoniae</i> (MICs to penicillin &le;2.0 mcg/mL), patient fully immunized for <i>H. influenzae</i> type b and <i>S. pneumoniae</i>, or minimal local resistance to penicillin in invasive pneumococcal strains (alternative to ampicillin or penicillin): 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe infection, patient not fully immunized for <i>H. influenzae</i> type b and <i>S. pneumoniae</i>, or significant local resistance to penicillin in invasive pneumococcal strains (preferred): 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe infection, <i>H. influenzae</i> (beta-lactamase producing) (preferred): 50 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sepsis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;12 years: IV: 150 mg/kg/day divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;50 kg or Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> Infants and Children: IV: 50 mg/kg every 6 hours, in combination with metronidazole or clindamycin for empiric therapy of polymicrobial infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> Children &ge;1 year: IV: 50 mg/kg within 60 minutes prior to surgical incision (maximum: 1000 mg per dose). Doses may be repeated in 3 hours if procedure is lengthy or if there is excessive blood loss. <b>Note:</b> preferred agent (with ampicillin) in liver transplantation (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Typhoid fever:</b> Infants and Children &le;12 years: IM, IV: 150 to 200 mg/kg/day in 3 to 4 divided doses (maximum: 12 g daily); fluoroquinolone resistant: 80 mg/kg/day in 3 to 4 divided doses (maximum: 12 g daily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147498\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147499\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Manufacturer&rsquo;s labeling: </i> <b>Note:</b> Renal function may be estimated using Cockcroft-Gault formula for dosage adjustment purposes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>: Dose should be decreased by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialysis: Moderately dialyzable (20% to 50%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Alternate recommendations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: The following dosage adjustments have been used by some clinicians (Aronoff 2007; Heintz 2009; Trotman 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR &gt;50 mL/minute:  Administer every 6 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR 10 to 50 mL/minute: Administer every 6 to 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR &lt;10 mL/minute: Administer every 24 hours <b>or</b> decrease the dose by 50% (and administer at usual intervals) (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent hemodialysis (IHD): Administer 1 to 2 g every 24 hours (on dialysis days, administer after hemodialysis). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peritoneal dialysis (PD): 1 g every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CVVH: 1 to 2 g every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CVVHD: 1 to 2 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CVVHDF: 1 to 2 g every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: <b>Note:</b> Glomerular filtration rate (GFR) should be estimated using an acceptable pediatric method (eg, Schwartz equation, Traub-Johnson equation, or a height/weight nomogram):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">The following dosage adjustments have been used by some clinicians (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Intermittent hemodialysis (IHD): 35 to 70 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Peritoneal dialysis: 35 to 70 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous renal replacement therapy (CRRT): 35 to 70 mg/kg/dose every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147500\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23083839\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147472\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claforan in D5W: 1 g/50 mL (50 mL [DSC]); 2 g/50 mL (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claforan: 500 mg (1 ea [DSC]); 1 g (1 ea [DSC]); 2 g (1 ea [DSC]); 10 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claforan: 1 g (1 ea [DSC]); 2 g (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147456\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147476\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject deep IM into large muscle mass. Individual doses of 2 g may be given if the dose is divided and administered in different IM sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Can be administered IV bolus over at least 3 to 5 minutes or as an IV intermittent infusion over 15 to 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147475\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacteremia/Septicemia:</b> Treatment of bacteremia/septicemia caused by <i>Escherichia coli</i>, <i>Klebsiella</i> species, and <i>Serratia marcescens</i>, <i>Staphylococcus aureus</i> and <i>Streptococcus</i> species (including <i>Streptococcus pneumoniae</i>). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Bone or joint infections:</b> Treatment of bone or joint infections caused by <i>S. aureus</i> (penicillinase and nonpenicillinase producing strains), <i>Streptococcus</i> species (including <i>Streptococcus pyogenes</i>), <i>Pseudomonas</i> species (including <i>Pseudomonas aeruginosa</i>), and <i>Proteus mirabilis</i>. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS infections:</b> Treatment of CNS infections (eg, meningitis, ventriculitis) caused by <i>Neisseria meningitidis</i>, <i>Haemophilus influenzae</i>, <i>S. pneumoniae</i>, <i>Klebsiella pneumoniae</i>, and <i>E. coli</i>. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Genitourinary infections:</b> Treatment of genitourinary infections, including urinary tract infections (UTIs), caused by <i>Enterococcus</i> species, <i>Staphylococcus epidermidis</i>, <i>S. aureus</i> (penicillinase and nonpenicillinase producing), <i>Citrobacter</i> species, <i>Enterobacter</i> species, <i>E. coli</i>, <i>Klebsiella</i> species, <i>P. mirabilis</i>, <i>Proteus vulgaris</i>, <i>Providencia stuartii</i>, <i>Morganella morganii</i>, <i>Providencia rettgeri</i>, <i>S. marcescens</i>, and <i>Pseudomonas</i> species (including <i>P. aeruginosa</i>). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by <i>Neisseria gonorrhoeae</i>, including penicillinase-producing strains. <b>Note:</b> CDC STD guidelines do not recommend cefotaxime as a treatment option for uncomplicated gonorrhea; ceftriaxone is the preferred cephalosporin (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gynecologic infections:</b> Treatment of gynecologic infections, including pelvic inflammatory disease, endometritis, and pelvic cellulitis, caused by <i>S. epidermidis</i>, <i>Streptococcus</i> species, <i>Enterococcus</i> species, <i>Enterobacter</i> species, <i>Klebsiella</i> species, <i>E. coli</i>, <i>P. mirabilis</i>, <i>Bacteroides</i> species (including <i>Bacteroides fragilis</i>), <i>Clostridium</i> species, and anaerobic cocci (including <i>Peptostreptococcus</i> and <i>Peptococcus</i> species) and <i>Fusobacterium</i> species (including <i>Fusobacterium nucleatum</i>). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections: </b>Treatment of intra-abdominal infections, including peritonitis caused by <i>Streptococcus</i> species, <i>E. coli</i>, <i>Klebsiella</i> species, <i>Bacteroides</i> species, and anaerobic cocci (including <i>Peptostreptococcus</i> species and <i>Peptococcus</i> species), <i>P. mirabilis</i>, and <i>Clostridium</i> species. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections:</b> Treatment of lower respiratory tract infections, including pneumonia, caused by <i>S. pneumoniae</i>, <i>S. pyogenes</i> (group A streptococci) and other streptococci (excluding enterococci, [eg, <i>Enterococcus faecalis</i>]), <i>S. aureus</i> (penicillinase and nonpenicillinase producing), <i>E. coli</i>, <i>Klebsiella</i> species, <i>H. influenzae</i> (including ampicillin-resistant strains), <i>H. parainfluenzae</i>, <i>P. mirabilis</i>, <i>S. marcescens</i>, <i>Enterobacter</i> species, and indole-positive <i>Proteus</i> and <i>Pseudomonas</i> species (including <i>P. aeruginosa</i>). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections caused by <i>S. aureus</i> (penicillinase and nonpenicillinase producing), <i>S. epidermidis</i>, <i>S. pyogenes</i> (group A streptococci) and other streptococci, <i>Enterococcus</i> species, <i>Acinetobacter</i> species, <i>E. coli</i>, <i>Citrobacter</i> species (including <i>Citrobacter freundii</i>), <i>Enterobacter</i> species, <i>Klebsiella</i> species, <i>P. mirabilis</i>, <i>P. vulgaris</i>, <i>M. morganii</i>, <i>P. rettgeri</i>, <i>Pseudomonas</i> species, <i>S. marcescens</i>, <i>Bacteroides</i> species, and anaerobic cocci (including <i>Peptostreptococcus</i> species and <i>Peptococcus</i> species). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis:</b> Reduce the incidence of certain infections in patients undergoing surgical procedures (eg, abdominal or vaginal hysterectomy, GI and GU tract surgery) that may be classified as contaminated or potentially contaminated; reduce the incidence of certain postoperative infections in patients undergoing cesarean section. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475333\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute bacterial rhinosinusitis; Bacterial enteric infections in HIV-infected patients (empiric treatment) (adolescents and adults); Bite wounds (animal); Community-acquired pneumonia (children); Disseminated gonococcal infection (DGI) (infants); Endocarditis, treatment (pediatric); Gonococcal scalp abscesses (infants); Gonococcal, disseminated infection (arthritis and arthritis-dermatitis syndrome); Lyme neuroborreliosis; Skin and soft tissue necrotizing infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147549\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cefotaxime may be confused with cefOXitin, cefuroxime</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Spectrocef [Italy] may be confused with Spectracef brand name for cefditoren [US, Great Britain, Mexico, Portugal, Spain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147463\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (&le;2%), skin rash (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Colitis (&le;1%), diarrhea (&le;1%), nausea (&le;1%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Induration at injection site (IM &le;4%), inflammation at injection site (IV &le;4%), pain at injection site (IM &le;4%), tenderness at injection site (IM &le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Acute generalized exanthematous pustulosis, acute renal failure, agranulocytosis, anaphylaxis, bone marrow failure, brain disease, candidiasis, cardiac arrhythmia (after rapid IV injection via central catheter), cholestasis, <i>Clostridium difficile</i> associated diarrhea, dizziness, erythema multiforme, granulocytopenia, headache, hemolytic anemia, hepatitis, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, injection site phlebitis, interstitial nephritis, jaundice, leukopenia, local irritation, neutropenia, pancytopenia, positive direct Coombs test, pseudomembranous colitis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147479\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefotaxime, any component of the formulation, or other cephalosporins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147460\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmia: A potentially life-threatening arrhythmia has been reported in patients who received a rapid (&lt;1 minute) bolus injection via central venous catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Granulocytopenia: Granulocytopenia and more rarely agranulocytosis may develop during prolonged treatment (&gt;10 days).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tissue inflammation: Minimize tissue inflammation by changing infusion sites when needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Colitis: Use with caution in patients with a history of colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\tDrug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298990\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147465\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9221&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cefotaxime. Management: Avoid cefotaxime doses greater than 6 g/day with concurrent probenecid.  Any patients receiving this combination should be monitored closely for evidence of cefotaxime toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147468\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951413\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Cefotaxime crosses the human placenta and can be found in fetal tissue. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins. During pregnancy, peak cefotaxime serum concentrations are decreased and the serum half-life is shorter. Cefotaxime is approved for use in women undergoing cesarean section (consult current guidelines for appropriate use).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147481\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low concentrations of cefotaxime are found in breast milk. The manufacturer recommends that caution be exercised when administering cefotaxime to nursing women. Nondose-related effects could include modification of bowel flora. The pregnancy-related changes in cefotaxime pharmacokinetics continue into the early postpartum period.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147482\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147470\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs and symptoms of anaphylaxis during first dose; CBC with differential (especially with long courses [&gt;10 days]); renal function </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147459\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Cefotaxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. <i>Enterococcus</i> species may be intrinsically resistant to cefotaxime. Most extended-spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefotaxime. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147478\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to body tissues and fluids including aqueous humor, ascitic and prostatic fluids, bone; penetrates CSF best when meninges are inflamed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 31% to 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Partially hepatic to active metabolite, desacetylcefotaxime </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefotaxime: Infants &le;1500 g: 4.6 hours; Infants &gt;1500 g: 3.4 hours; Children: 1.5 hours; Adults: 1 to 1.5 hours; prolonged with renal and/or hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Desacetylcefotaxime: 1.3 to 1.9 hours; prolonged with renal impairment (Ings 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: Within 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~60% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323047\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefotaxime Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $32.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $1.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147483\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benaxima (MX);</li>\n      <li>Biosint (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Biotax (IN);</li>\n      <li>Cefacolin (AR);</li>\n      <li>Cefalekol (HU);</li>\n      <li>Cefirad (KR);</li>\n      <li>Cefocam (PY);</li>\n      <li>Cefot (BD);</li>\n      <li>Cefotaksim (HR);</li>\n      <li>Cefotax (AE, BH, CY, EG, IQ, IR, JO, JP, KW, LB, LY, OM, RO, SA, SY, YE);</li>\n      <li>Cefotaxim (DE, NO);</li>\n      <li>Cefotrial (PE);</li>\n      <li>Cefox (PH);</li>\n      <li>Cefoxim (KR);</li>\n      <li>Cefpiran (KR);</li>\n      <li>Ceftax (AE, BH, JO, QA, SA);</li>\n      <li>Cetax (TW);</li>\n      <li>Clacef (ID);</li>\n      <li>Cladex (PH);</li>\n      <li>Claforan (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CR, CY, DK, DO, EC, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PH, PK, PY, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Clafotax (BH, JO, KW, QA, SA);</li>\n      <li>Claraxim (TH);</li>\n      <li>Clatax (ID);</li>\n      <li>Clavox (TW);</li>\n      <li>Diabec (BD);</li>\n      <li>Efotax (ID);</li>\n      <li>Fahotsef (UA);</li>\n      <li>Fot-Amsa (MX);</li>\n      <li>Fotax (BD);</li>\n      <li>Fotexina (CO, CR, DO, EC, GT, HN, MX, NI, PA, SV);</li>\n      <li>Glocef (ID);</li>\n      <li>Gloryfen (LB, MT);</li>\n      <li>Grifotaxima (CL);</li>\n      <li>Haxim (PH);</li>\n      <li>Kalfoxim (ID);</li>\n      <li>Lancef (ID);</li>\n      <li>Lapixime (ID);</li>\n      <li>Letynol (MT);</li>\n      <li>Loraksym (UA);</li>\n      <li>Lyforan (IN);</li>\n      <li>Makrocef (HR);</li>\n      <li>Molelant (GR);</li>\n      <li>Necaxime (TH);</li>\n      <li>Newtaxime (KR);</li>\n      <li>Novatax (LK);</li>\n      <li>Omnatax (IN);</li>\n      <li>Oritaxim (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Oritaxim-1000 (LK);</li>\n      <li>Pantaxin (PH);</li>\n      <li>Primocef (AE);</li>\n      <li>Procefa (ID);</li>\n      <li>Racotax (LK);</li>\n      <li>Ralopar (PT);</li>\n      <li>Reftax (ZA);</li>\n      <li>Rekaxime (MY);</li>\n      <li>Saifulong (CN);</li>\n      <li>Sefotak (AE, BH, CY, CZ, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Soclaf (ID);</li>\n      <li>Spirosine (GR);</li>\n      <li>Stoparen (GR, LB);</li>\n      <li>Talcef (PE);</li>\n      <li>Taporin (MX);</li>\n      <li>Taxibiotic (VN);</li>\n      <li>Taxim (BD);</li>\n      <li>Taximax (ID);</li>\n      <li>Taxime (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Taximed (CZ);</li>\n      <li>Taximmed (VN);</li>\n      <li>Tebruxim (MX);</li>\n      <li>Tirdicef (ID);</li>\n      <li>Tirotax (MX, PL, QA);</li>\n      <li>Ultracef (UY);</li>\n      <li>Unitax (TW);</li>\n      <li>Valoran (EE, MT);</li>\n      <li>Viken (MX);</li>\n      <li>Xedin (MX);</li>\n      <li>Xendin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ximvex (PH);</li>\n      <li>Zariviz (IT);</li>\n      <li>Zefocent (PH);</li>\n      <li>Zefotax (PH);</li>\n      <li>Zentro (PH);</li>\n      <li>Zetax (ET)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 55, 149.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogden RN and Spencer CM, &ldquo;Cefotaxime. A Reappraisal of Its Antibacterial Activity and Pharmacokinetic Properties, and a Review of Its Therapeutic Efficacy When Administered Twice Daily for the Treatment of Mild-to-Moderate Infections,&rdquo; <i>Drugs</i>, 1997, 53(3):483-510.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/9074846/pubmed\" target=\"_blank\" id=\"9074846\">9074846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claforan (cefotaxime) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deeter RG, Weinstein MP, Swanson KA, et al, &ldquo;Crossover Assessment of Serum Bactericidal Activity and Pharmacokinetics of Five Broad-Spectrum Cephalosporins in the Elderly,&rdquo; <i>Antimicrob Agents Chemother</i>, 1990, 34(6):1007-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/2393258/pubmed\" target=\"_blank\" id=\"2393258\">2393258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17522387\"></a>Halperin JJ, Shapiro ED, Logigian E, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2007;69(1):91-102<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ings, RMJ, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. <i>Rev Infect Dis</i>. 1982;4(suppl): S379-S391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/6294787 /pubmed\" target=\"_blank\" id=\"6294787 \">6294787 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein NC and Cunha BA, &ldquo;Third-Generation Cephalosporins,&rdquo; <i>Med Clin North Am</i>, 1995, 79(4):705-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/7791418/pubmed\" target=\"_blank\" id=\"7791418\">7791418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19783532\"></a>Lim WS, Baudouin SV, George RC, et al; Woodhead MA; Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. <i>Thorax</i>. 2009;64(suppl 3):iii1-iii55. doi:10.1136/thx.2009.121434<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/19783532/pubmed\" target=\"_blank\" id=\"19783532\">19783532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludwig E, Sz&eacute;kely &Eacute;, Csiba A, et al, &ldquo;Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Elderly Patients,&rdquo; <i>Drugs</i>, 1988, 35(Suppl 2):51-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/3396489/pubmed\" target=\"_blank\" id=\"3396489\">3396489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17278083\"></a>Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(suppl 2):S27-S72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 6, 2015.23463403</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spritzer R, Kamp HJ, Dzoljic G, et al, &ldquo;Five Years of Cefotaxime Use in a Neonatal Intensive Care Unit,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(2):92-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/2179846/pubmed\" target=\"_blank\" id=\"2179846\">2179846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wise R, Wright N. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction. <i>Infection</i>. 1985;13(suppl 1):S145-S150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/4055047 /pubmed\" target=\"_blank\" id=\"4055047 \">4055047 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(9):1089-1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9221 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F147493\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147494\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F147542\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F147497\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F147520\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F147498\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F147499\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F147500\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F23083839\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147472\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F147456\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F147476\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F147475\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475333\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147549\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147463\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147479\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147460\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298990\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147465\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147468\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5951413\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F147481\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F147482\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F147470\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147459\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F147478\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323047\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147483\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9221|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefotaxime-patient-drug-information\" class=\"drug drug_patient\">Cefotaxime: Patient drug information</a></li><li><a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefotaxime: Pediatric drug information</a></li></ul></div></div>","javascript":null}